STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: Validating the promise of molecularly targeted therapy Academic Article Article uri icon


MeSH Major

  • Antigens, CD34
  • Antigens, CD38
  • Antineoplastic Agents
  • Chromosome Aberrations
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases


  • The deregulated tyrosine kinase activity of the Bcr-Abl fusion protein has been established as the causative molecular event in chronic myelogenous leukemia (CML). Thus the Bcr-Abl tyrosine kinase is an ideal target for pharmacologic inhibition. ST1571 (formerly CGP57148B), is an Abl-specific tyrosine kinase inhibitor that in preclinical studies selectively kills Bcr-Abl-containing cells in vitro and in vivo. The results of clinical studies have demonstrated the potential of molecularly targeted therapies, and ST1571 is emerging as a new therapeutic agent for CML.

publication date

  • December 2001



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1007/s002800100310

PubMed ID

  • 11587372

Additional Document Info

start page

  • S77

end page

  • 8


  • 48


  • SUPPL. 1